ArticleMolecular cancer therapeutics2021
Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 82 citations in OpenAlex.
- Live-Cell Optical Redox Imaging Reveals Metabolic Heterogeneity and Context-Dependent Responses to Metabolic Perturbation in TNBC Cells.Metabolites · 2026Article
- Live cell imaging reveals paclitaxel-induced lysosome motility and function disruption in DRG neurons.bioRxiv : the preprint server for biology · 2026Article
- Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion.Cell reports. Medicine · 2026Article
- Recent paclitaxel formulation strategies: expanding the therapeutic index by addressing biopharmaceutical and toxicity limitations.Archives of pharmacal research · 2026Review
- A STING signaling relay from tumor cells to macrophages mediates the improved efficacy of combination chemotherapy in pancreatic cancer.Journal of biomedical science · 2026Article
- The cGAS-STING pathway in cancer immunotherapy: prognostic value and therapeutic potential.Frontiers in immunology · 2026Review
- Mechanism-based management of taxane-induced neuropathic pain in breast cancer survivors: a critical review.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Mitotic errors as triggers of cell death and inflammation.Nature cell biology · 2026Review
- The cGAS-STING pathway in tumor immunity: dual roles, regulatory mechanisms, and precision therapeutic strategies.Frontiers in pharmacology · 2026Review
- Targeting the redox-programmed cell death axis in breast cancer: from molecular mechanisms to therapeutic resistance.Cell death discovery · 2025Review
- Therapeutic connections between pyroptosis and paclitaxel in anti-tumor effects: an updated review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Innate Immune Surveillance and Recognition of Epigenetic Marks.Epigenomes · 2025Review
- Decoy DNA Protects Molecular Tension Probes from DNase Degradation.Angewandte Chemie (International ed. in English) · 2025Article
- Molecular features of TNBC govern heterogeneity in the response to radiation and autophagy inhibition.Cell death & disease · 2025Article
- Tick-Tock: Cancer Cell Division Cycle Clocks Strike Midnight.International journal of molecular sciences · 2025Review
- The cGAS-STING axis: a comprehensive review from immune defense to disease pathogenesis.Immunologic research · 2025Review
- cGAS/STING-Independent Induction of Type I Interferon by Inhibitors of the Histone Methylase KDM5B.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Development and validation of a functional ex vivo paclitaxel and eribulin sensitivity assay for breast cancer, the REMIT assay.NPJ breast cancer · 2025Article
- Small Molecules Identified by an In Silico Docking Screen Targeting Anaphase-Promoting Complex/Cyclosome Subunit 1 (APC1) Potentiate Paclitaxel-Induced Breast Cancer Cell Death.Molecules (Basel, Switzerland) · 2025Article
- TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Yang HuDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-3068-7136
Baraa K ManasrahDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Stephanie M McGregorUW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-7940-1143
Robert F LeraDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0001-8713-4279
Roshan X NormanDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-2444-519X
John B TuckerMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin.
Christina M ScribanoMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin.
Rachel E YanDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Mouhita HumayunUW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Kari B WisinskiDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0003-3535-0652
Amye J TevaarwerkDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-8087-5119
Ruth M O'ReganDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin.
Lee G WilkeUW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Beth A WeaverMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin.
David J BeebeUW Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
Ning JinDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin. mburkard@wisc.edu ning.jin2@osumc.edu.
Mark E BurkardDepartment of Medicine, Hematology/Oncology, University of Wisconsin-Madison, Madison, Wisconsin. mburkard@wisc.edu ning.jin2@osumc.edu.ORCID 0000-0002-4215-7722
University of Wisconsin–Madison · USUniversity of Wisconsin System · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6MTraining in Cancer Biology Training GrantT32CA009135 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SUGDEN, WILLIAM M. · 1985 to 2024
$10.4MINTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3MRESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2MIntegrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5MMicroscale models of inflammation and its resolutionR01AI134749 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BEEBE, DAVID J, HUTTENLOCHER, ANNA · 2018 to 2022
$3.8MAn automated high-throughput tissue model for screening metastatic effectorsR01CA186134 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEEBE, DAVID J · 2015 to 2019
$3.1MImpact of chromosomal instability on sensitivity to microtubule-targeting drugs in breast cancerR01CA234904 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E, WEAVER, BETH A · 2019 to 2023
$2.7MTargeting cancer-stroma interactions in breast cancer metastasis using organotypic modelingF31CA247248 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI HUMAYUN, MOUHITA · 2019 to 2021
$67kNCI NIH HHS F31 CA247248NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA186134NCI NIH HHS R01 CA234904NCI NIH HHS T32 CA009135NHLBI NIH HHS T32 HL007899NIAID NIH HHS R01 AI134749NIGMS NIH HHS T32 GM008692NIGMS NIH HHS T32 GM140935
Abstract
Taxanes remain one of the most effective medical treatments for breast cancer. Clinical trials have coupled taxanes with immune checkpoint inhibitors in patients with triple-negative breast cancer (TNBC) with promising results. However, the mechanism linking taxanes to immune activation is unclear. To determine if paclitaxel could elicit an antitumoral immune response, we sampled tumor tissues from patients with TNBC receiving weekly paclitaxel (80 mg/m
Indexed as
Antineoplastic Agents, PhytogenicCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansInflammationNucleotidyltransferasesPaclitaxelSignal TransductionTaxoidsTriple Negative Breast NeoplasmsAntineoplastic Agents, PhytogeniccGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseNucleotidyltransferasesPaclitaxelTaxoids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.